- Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
- Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
- Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Tourmaline Bio Announces Pricing of Public Offering of Common Stock
- Tourmaline Bio Announces Proposed Public Offering of Common Stock
- Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
- Tourmaline Bio added to the NASDAQ Biotechnology Index
- Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
More ▼
Key statistics
On Thursday, Tourmaline Bio Inc (TRML:NSQ) closed at 13.66, 48.80% above the 52 week low of 9.18 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.83 |
---|---|
High | 13.83 |
Low | 13.16 |
Bid | 12.58 |
Offer | 13.96 |
Previous close | 13.63 |
Average volume | 243.88k |
---|---|
Shares outstanding | 25.65m |
Free float | 19.85m |
P/E (TTM) | -- |
Market cap | 349.56m USD |
EPS (TTM) | -5.35 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼